URAC and ACHC Specialty Accreditation, HIPAA, Manufacturer Data Reporting Agreements, Anti-Kickback Limits on Patient Assistance and REMS Program Requirements: Compliance for US Specialty Pharmacy Software

Five Surfaces, and They Shape the Product

Five compliance surfaces apply here, which is more than almost any category, and unusually they determine the product’s structure rather than sitting alongside it, which is what makes specialty pharmacy compliance software an architectural subject.

Accreditation standards set what the organization must do and document. Privacy law governs every piece of patient information. Manufacturer agreements bound what may be reported. Anti-kickback provisions determine which patients may receive which assistance. And risk management programs determine whether a dispense may happen at all.

A platform designed around workflows and reviewed afterwards will need rebuilding in at least two places, because two of these are architecture rather than features: the payer bifurcation and the reporting boundary. Specialty pharmacy compliance software is therefore specified before design, not after.

Which is why this article sits in the middle of the cluster and why the scoping article that follows treats these as the first questions.

This is educational content, not legal advice, and requirements differ by accrediting body, by manufacturer and by program. Compliance is the architectural layer of the full custom software development guide to custom specialty pharmacy hub platform development, expressed through web application development in the systems staff actually use.

Anti-Kickback Limits on Patient Assistance

Why Federally Insured Patients Are Treated Differently

The federal anti-kickback statute and beneficiary inducement provisions address remuneration intended to induce the purchase or ordering of items reimbursable by federal healthcare programs.

Manufacturer copay assistance provided to a beneficiary of such a program implicates those provisions, which is why it is generally not offered to them. The analysis and the guidance behind it belong with counsel.

Independent Charitable Foundations

Foundations supported by manufacturer donations may assist patients including federally insured ones, with guidance addressing how independence is maintained: the donor not controlling or directing awards, funds defined by disease state rather than by product, and the donor not receiving information enabling it to correlate donations with use of its products.

The separation is the basis on which these arrangements are evaluated.

What This Means Structurally

The platform makes manufacturer copay enrollment unavailable to federally insured patients by construction, detects payer type changes that alter eligibility mid-therapy, builds the foundation path as a genuine workflow, and holds the separation absolutely in both directions.

These are not rules an administrator configures.

URAC and ACHC Specialty Accreditation

The standards that determine whether an organization can participate in networks at all, which makes them commercially decisive rather than merely good practice.

Specialty pharmacy accreditation programs operated by recognized accrediting bodies set standards covering organizational structure and governance, patient management and clinical services, medication management, performance measurement and quality improvement, privacy and information security, and operational processes including shipping and storage.

Several bodies accredit in this space with differing emphases, and many organizations hold more than one because payers and manufacturers specify different ones.

Standards are revised on cycles and specific requirements differ between bodies and versions, which means an article should describe the structure and point at the current standards rather than enumerate them.

The practical consequence for a platform is substantial. Accreditation expects defined processes, consistent documentation of patient management activities, measurement of specified performance metrics collected systematically, and evidence of quality improvement activity.

Which turns performance measurement from a reporting feature into a standing operational requirement, and turns documentation standards into field-level design decisions.

An organization seeking accreditation for the first time will find the measurement requirements the hardest part, since retrospective collection is painful and the metrics must be gathered as work happens.

Work from the current standards of your accrediting bodies, and never publish them. Establishing your position on each of these is what scoping does, covered in Scoping Before Coding.

HIPAA and Manufacturer Data Reporting Agreements

Two surfaces that interact constantly, since the second is largely about how the first applies to a commercial relationship.

All patient information in this system is protected health information. The privacy and security rules impose minimum necessary standards on use and disclosure, access controls, audit controls, workforce training, breach notification and business associate obligations extending to vendors.

In a hub context the roles need establishing carefully: who is a covered entity, who is a business associate, and in what capacity each party acts, since hub arrangements can be structurally complicated.

Manufacturer data agreements then govern what may be reported, in what form, how often and with what protections, alongside the patient authorizations obtained at enrollment, which define what the patient agreed to.

Those authorizations matter and are frequently treated as paperwork. What a patient authorized is a boundary on what may flow.

For the platform: reporting as a bounded output per program with de-identification or aggregation applied by construction, field-level control, an audit record of transmissions against agreement versions, role-based access reflecting minimum necessary, and authorization status held against the patient record.

Obtain healthcare regulatory counsel and work from current agreements, and never publish terms.

REMS Program Requirements

The surface where software’s correct behavior is to stop, which is unusual and worth stating plainly.

Risk evaluation and mitigation strategies are required for certain drugs where they are necessary to ensure benefits outweigh risks. Where a strategy includes elements to assure safe use, those may require prescriber certification, pharmacy certification, patient enrollment, documented counseling, laboratory monitoring at defined intervals, dispensing only in certain settings, and documented verification before each dispense.

Requirements differ by program, and some programs are shared across multiple products with a single system.

A pharmacy dispensing under such a program operates within its requirements, and the required verification generally occurs through the program’s own system rather than the pharmacy’s.

Which gives the platform a defined and limited role: holding certification status, tracking monitoring intervals, recording that required verification was performed by the required person through the required mechanism, and blocking a dispense where it was not.

No override. No warning that can be dismissed. No software determination that a condition has been satisfied in place of the actual verification.

Patient-level status and interval tracking matter, since a monitoring result coming due is a scheduling task before it is a block.

Work from each program’s current requirements, and never publish them.

Other Obligations

State pharmacy licensure, including non-resident licensure where a pharmacy ships across state lines, which for specialty is most of them. Pharmacist and nurse licensure by state for clinical services.

Controlled substance requirements where applicable to the therapies dispensed. Adverse event reporting obligations, which attach to anybody receiving safety information.

Drug supply chain security requirements for product tracing. Cold chain and storage requirements with documentation.

340B program considerations where a covered entity or contract pharmacy arrangement is involved. Payer contracts and network participation requirements.

State assistance and transparency laws, several of which address copay programs. Telehealth requirements where clinical services are delivered remotely across state lines. And record retention across clinical, dispensing and program documentation.

What This Means for the Build

Five positions follow, and two precede architecture rather than informing it, which is the distinguishing feature of specialty pharmacy compliance software.

Assistance routing bifurcated structurally on payer type, with manufacturer copay enrollment unavailable by construction to federally insured patients and payer change detection built in.

Manufacturer reporting as a bounded per-program output with de-identification by construction and transmission audit, never an export capability.

REMS and limited distribution conditions implemented as dispensing blocks with no override path.

Accreditation performance metrics collected as work happens rather than assembled retrospectively, since that is where first-time accreditation efforts fail.

And role-based access reflecting minimum necessary, with manufacturer-facing views structurally separate from the clinical record.

The first two cannot be retrofitted without substantial rebuilding, which is why counsel and the compliance officer belong in scoping rather than in review. Which obligations become concrete product structure is mapped in Specialty Pharmacy Software Features.

Conclusion

Build the payer bifurcation and the reporting boundary as architecture, since both are structural and neither retrofits.

Implement dispensing conditions as blocks rather than warnings. Collect accreditation metrics as work happens, because retrospective assembly is where first accreditation attempts fail. And establish the privacy roles in your hub arrangement carefully, since they are less obvious than they look.

This is educational content, not legal advice. Work with healthcare regulatory counsel, your compliance officer, your accrediting bodies and current manufacturer agreements, then brief the software companies in the United States quoting you on where the platform’s job stops.

If you are scoping a platform, asking whether a coordinator could today enroll a Medicare patient in manufacturer copay assistance is the question that tests your architecture.

FAQ